Febuxostat improves outcome in a rat model of cancer cachexia

Journal of Cachexia, Sarcopenia and Muscle

Volumn , Issue , 2015, Pages 174-180

  Konishi, Masaaki ^a   Pelgrim, Loes ^b,c   Tschirner, Anika ^b   Baumgarten, Anna ^b   von Haehling, Stephan ^a   Palus, Sandra ^a   Doehner, Wolfram ^b   Anker, Stefan D ^a   Springer, Jochen ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

Cancer cachexia; Survival; Wasting; Weight loss; Yoshida hepatoma animal model

Indexed keywords

FEBUXOSTAT; PLACEBO; PROTEIN KINASE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY COMPOSITION; CACHEXIA; CONTROLLED STUDY; FAT MASS; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE SIZE; HEART STROKE VOLUME; NONHUMAN; ORGAN WEIGHT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; QUALITY OF LIFE; RAT; TUMOR GROWTH; WEIGHT CHANGE;

EID: 84982129695     PISSN: 21905991     EISSN: 21906009     Source Type: Journal    
DOI: 10.1002/jcsm.12017     Document Type: Article

References (32)

1. Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr 2008; 27: 793–799.
2. Farkas J, von Haehling S, Kalantar-Zadeh K, Morley JE, Anker SD, Lainscak M. Cachexia as a major public health problem: frequent, costly, and deadly. J Cachexia Sarcopenia Muscle 2013; 4: 173–178.
3. von Haehling S, Anker SD. Cachexia vs obesity: where is the real unmet clinical need? J Cachexia Sarcopenia Muscle 2013; 4: 245–246.
4. Hammarsten J, Hogstedt B. Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer. Blood Press 2004; 13: 47–55.
5. Shin HS, Lee HR, Lee DC, Shim JY, Cho KH, Suh SY. Uric acid as a prognostic factor for survival time: a prospective cohort study of terminally ill cancer patients. J Pain Symptom Manage 2006; 31: 493–501.
6. Terada LS, Guidot DM, Leff JA, Willingham IR, Hanley ME, Piermattei D, et al. Hypoxia injures endothelial cells by increasing endogenous xanthine oxidase activity. Proc Natl Acad Sci U S A 1992; 89: 3362–3366.
7. Powers SK, Kavazis AN, DeRuisseau KC. Mechanisms of disuse muscle atrophy: role of oxidative stress. Am J Physiol Regul Integr Comp Physiol 2005; 288: R337–R344.
8. Springer J, Tschirner A, Hartman K, Palus S, Wirth EK, Ruis SB, et al. Inhibition of xanthine oxidase reduces wasting and improves outcome in a rat model of cancer cachexia. Int J Cancer 2012; 131: 2187–2196.
9. Arellano F, Sacristan JA. Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother 1993; 27: 337–343.
10. Takano Y, Hase-Aoki K, Horiuchi H, Zhao L, Kasahara Y, Kondo S, et al. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci 2005; 76: 1835–1847.
11. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353: 2450–2461.
12. Costelli P, Carbo N, Tessitore L, Bagby GJ, Lopez-Soriano FJ, Argiles JM, et al. Tumor necrosis factor-alpha mediates changes in tissue protein turnover in a rat cancer cachexia model. J Clin Invest 1993; 92: 2783–2789.
13. Stimpson SA, Leonard MS, Clifton LG, Poole JC, Turner SM, Shearer TW, et al. Longitudinal changes in total body creatine pool size and skeletal muscle mass using the D-creatine dilution method. J Cachexia Sarcopenia Muscle 2013; 4: 217–223.
14. Tschirner A, von Haehling S, Palus S, Doehner W, Anker SD, Springer J. Ursodeoxycholic acid treatment in a rat model of cancer cachexia. J Cachexia Sarcopenia Muscle 2012; 3: 31–36.
15. Akashi YJ, Palus S, Datta R, Halem H, Taylor JE, Thoene-Reineke C, et al. No effects of human ghrelin on cardiac function despite profound effects on body composition in a rat model of heart failure. Int J Cardiol 2009; 137: 267–275.
16. Springer J, Tschirner A, Haghikia A, von Haehling S, Lal H, Grzesiak A, et al. Prevention of liver cancer cachexia-induced cardiac wasting and heart failure. Eur Heart J 2014; 35: 932–941.
17. Lenk K, Palus S, Schur R, Datta R, Dong J, Culler MD, et al. Effect of ghrelin and its analogues, BIM-28131 and BIM-28125, on the expression of myostatin in a rat heart failure model. J Cachexia Sarcopenia Muscle 2013; 4: 63–69.
18. Fanzani A, Conraads VM, Penna F, Martinet W. Molecular and cellular mechanisms of skeletal muscle atrophy: an update. J Cachexia Sarcopenia Muscle 2012; 3: 163–179.
19. Wu M, Falasca M, Blough ER. Akt/protein kinase B in skeletal muscle physiology and pathology. J Cell Physiol 2011; 226: 29–36.
20. 2 induce caspase-3-independent degradation of Akt/protein kinase B. J Biol Chem 2002; 277: 42943–42952.
21. Xu X, Hu X, Lu Z, Zhang P, Zhao L, Wessale JL, et al. Xanthine oxidase inhibition with febuxostat attenuates systolic overload-induced left ventricular hypertrophy and dysfunction in mice. J Card Fail 2008; 14: 746–753.
22. Malik UZ, Hundley NJ, Romero G, Radi R, Freeman BA, Tarpey MM, et al. Febuxostat inhibition of endothelial-bound XO: implications for targeting vascular ROS production. Free Radic Biol Med 2011; 51: 179–184.
23. Hwang SJ, Lee KH, Jang HH, Lee SR, Woo JS, Lee HJ, et al. Febuxostat contributes to improvement of endothelial dysfunction in an experimental model of streptozocin-induced diabetic rats. Int J Cardiol 2014; 171: e110–e112.
24. Hou M, Hu Q, Chen Y, Zhao L, Zhang J, Bache RJ. Acute effects of febuxostat, a nonpurine selective inhibitor of xanthine oxidase, in pacing induced heart failure. J Cardiovasc Pharmacol 2006; 48: 255–263.
25. Nomura J, Busso N, Ives A, Tsujimoto S, Tamura M, So A, et al. Febuxostat, an inhibitor of xanthine oxidase, suppresses lipopolysaccharide-induced MCP-1 production via MAPK phosphatase-1-mediated inactivation of JNK. PLoS One 2013; 8: e75527.
26. Szasz T, Davis RP, Garver HS, Burnett RJ, Fink GD, Watts SW. Long-term inhibition of xanthine oxidase by febuxostat does not decrease blood pressure in deoxycorticosterone acetate (DOCA)-salt hypertensive rats. PLoS One 2013; 8: e56046.
27. Sezai A, Soma M, Nakata K, Hata M, Yoshitake I, Wakui S, et al. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients (NU-FLASH Trial). Circ J 2013; 77: 2043–2049.
28. Tausche AK, Christoph M, Forkmann M, Richter U, Kopprasch S, Bielitz C, et al. As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout. Rheumatol Int 2014; 34: 101–109.
29. Springer J, Tschirner A, Hartman K, von Haehling S, Anker SD, Doehner W. The xanthine oxidase inhibitor oxypurinol reduces cancer cachexia-induced cardiomyopathy. Int J Cardiol 2013; 168: 3527–3531.
30. Coats AJ. Research on cachexia, sarcopenia and skeletal muscle in cardiology. J Cachexia Sarcopenia Muscle 2012; 3: 219–223.
31. Schmidt K, von Haehling S, Doehner W, Palus S, Anker SD, Springer J. IGF-1 treatment reduces weight loss and improves outcome in a rat model of cancer cachexia. J Cachexia Sarcopenia Muscle 2011; 2: 105–109.
32. Sakuma K, Yamaguchi A. Sarcopenia and cachexia: the adaptations of negative regulators of skeletal muscle mass. J Cachexia Sarcopenia Muscle 2012; 3: 77–94.